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Abstract
Background: One goal of gene expression profiling is to identify signature genes that robustly
distinguish different types or grades of tumors. Several tumor classifiers based on expression
profiling have been proposed using microarray technique. Due to important differences in the
probabilistic models of microarray and SAGE technologies, it is important to develop suitable
techniques to select specific genes from SAGE measurements.
Results: A new framework to select specific genes that distinguish different biological states based
on the analysis of SAGE data is proposed. The new framework applies the bolstered error for the
identification of strong genes that separate the biological states in a feature space defined by the
gene expression of a training set. Credibility intervals defined from a probabilistic model of SAGE
measurements are used to identify the genes that distinguish the different states with more
reliability among all gene groups selected by the strong genes method. A score taking into account
the credibility and the bolstered error values in order to rank the groups of considered genes is
proposed. Results obtained using SAGE data from gliomas are presented, thus corroborating the
introduced methodology.
Conclusion: The model representing counting data, such as SAGE, provides additional statistical
information that allows a more robust analysis. The additional statistical information provided by
the probabilistic model is incorporated in the methodology described in the paper. The introduced
method is suitable to identify signature genes that lead to a good separation of the biological states
using SAGE and may be adapted for other counting methods such as Massive Parallel Signature
Sequencing (MPSS) or the recent Sequencing-By-Synthesis (SBS) technique. Some of such genes
identified by the proposed method may be useful to generate classifiers.
Background
Using high-throughput molecular approaches, mainly
microarrays, several groups of genes have been identified
to be associated with cancer [1-8]. Molecular profiles have
been associated with specific histologic and prognostic
tumor subgroups, but the number of genes in the different
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profiles is too high to be used as signatures for classifica-
tion. The limited amount of available human tissues and
the cost of gene expression screening projects yield the
search for classifiers that only depend on small sets of
genes. In the pattern recognition literature, the problem of
finding a subspace of variables that is enough to distin-
guish classes of patterns is known as dimensionality
reduction. Despite the existence of a large literature about
dimensionality reduction [9], most of it does not apply
for classification from gene expression vectors due to lack
of observed data. Typically, we have spaces of some thou-
sands of genes and would like to get subspaces of two or
three genes from the observation of some dozens of
expression vectors. To overcome this difficulty, the strong
genes technique adopts a probabilistic model for the ran-
dom vector distribution of each class: the union of round
uniform spread functions, which are estimated from the
observed data [10]. The strong genes technique was pro-
posed in [10] and used for glioma classification with
microarrays. The estimated model is projected onto a sub-
space of a small number of variables n where the error of
the optimum linear classifier is computed. This procedure
is repeated for all subspaces of n variables and the genes
n-tuple quality is evaluated by the corresponding classifi-
cation error: the best n-tuples generate the best separators
and, therefore, those that have smallest errors. The origi-
nal version of this procedure requires hours in a super-
computer. Nevertheless, an approximation technique was
recently developed which requires just some minutes in a
conventional desktop computer [11].
A large scale approach widely used in gene expression
studies is the Serial Analysis of Gene Expression (SAGE)
[12]. SAGE uses a very different approach compared to
microarrays for measuring mRNA levels. First, double
stranded cDNA is created from the mRNA. A single 10
base pair "sequence tag" is cut from a specific location in
each cDNA. The sequence tags are concatenated into a
long double stranded DNA which can then be amplified
and sequenced. The expression of a gene in a given exper-
iment is estimated just by counting the number of tags in
the sequence corresponding to that gene, thus providing
absolute transcript numbers and allowing statistical com-
parisons of data from multiple laboratories.
Vêncio et al. [13] modeled SAGE gene expression meas-
urements by a Beta distribution and applied Bayesian esti-
mation to calculate the corresponding credibility interval,
thus providing an important tool for statistical analysis of
SAGE data. It is important to note that, in contrast to
microarray where the data formation probabilistic model
is unknown, the model representing SAGE gene expres-
sion provides further statistical information that allows a
more robust analysis. The additional statistical informa-
tion provided by the probabilistic model is incorporated
in the methodology described in the paper. We explored
the SAGE statistical model and modified the strong genes
technique in order to make it suitable for distinguishing
classes of patterns from SAGE measurements. Due to
important differences in the probabilistic models of
microarray and SAGE technologies, we propose the con-
cept of subspace credibility. This concept, based on the
aforementioned credibility intervals of SAGE measure-
ments introduced in [13], is used to complement the
application of the strong genes technique. The credibility
gives a measure of the distance between the two classes
according to the credibility interval model. The best cho-
sen subspaces are those that have both minimum bol-
stered error (computed by the strong gene technique) and
maximum credibility. A score taking into account these
two measures is proposed in the present work.
Therefore, the resulting new methodology allows the
application of the strong genes technique to SAGE data in
order to select gene subspaces in a consistent way under
the perspective of the aforementioned SAGE gene expres-
sion measurements model. The double criterion allows
gene selection in a more feasible way when SAGE data is
involved. The proposed technique was applied to distin-
guish glioma tumors and the results are reported. Accord-
ing to the World Health Organization (WHO)
classification of brain tumors, gliomas are divided in low-
grade (grades I and II) and high-grade (grades III and IV)
tumors. Low-grade tumors are well-differentiated, slow-
growing lesions. Grade I tumors are well-circumscribed
and often curable, whereas grade II, III and IV tumors are
diffuse, infiltrating lesions. Grade II tumors have a
marked potential overtime for progression towards a
high-grade malignant tumor.
Results
The introduced methodology was applied to SAGE data to
identify genes that were putatively related to neurological
tumor progression. Table 1 shows the different anato-
mopathological comparisons and the number of libraries
in each class.
The first 1000 ranked triples according to the introduced
approach (refer to the Methods section below) were con-
sidered out of about 908 billion possible triples. The sets
of triples obtained in all comparisons ordered by the bol-
stered error and by the introduced score (Equation 3, see
Methods section) are available at the supplemental mate-
rial web-site [14]. Figure 1 shows a list of the first 10
ranked triples in the normal × glioblastoma comparison.
When the compared classes are very distant with respect to
the error, it is very difficult to choose the best triple from
the first 1000 ones because either the errors are very small
(zero for six or more significant digits) or they are very
similar. This fact is due to the small sample size. When theBMC Bioinformatics 2007, 8:169 http://www.biomedcentral.com/1471-2105/8/169
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distance between classes is smaller, although the triples
may be ranked using the error, it is still difficult to choose
the best triple since the error variation between the triples
is too small. In order to circumvent these problems, it is
important to take into account the credibility measure for
each expression measurement based on the total number
of tags counted in each library. This is accomplished by
the score measure defined by Equation 3 which incorpo-
rates the error and the credibility measures to rank the tri-
ples. The application of the score shows that, despite of a
low error and a large distance, some triples are no longer
ranked in the top positions as they were by only using the
error criterion because the credibility value is too low. This
means that the proximity of some samples of one group
with samples of the other may be large considering the
location, volume and edge size of each credibility interval
box. Figure 3 shows an example of a three-dimensional
plot representing the credibility interval boxes for the best
triple produced by the system for the astrocytoma III vs
glioblastoma experiment. Note that this triple reliably sep-
arates the two classes taking into account the credibility
boxes.
Table 2 presents the bolstered error along with its stand-
ard deviation and the average distance of the nearest point
from the hyperplane, for the first 50 triples from each
comparison, ranked by the bolstered error and by the
score, as well as a list of the ten most frequent genes along
the 50 best triples. The first comparison was normal brain
against glioblastoma multiform (GB) since we expected
the largest difference in this combination of classes.
According to Table 1, this comparison comprises 2 versus
9 libraries for normal and GB, respectively. As expected for
the first comparison, the obtained bolstered error is the
smallest among all class comparisons and the distance is
the largest one. In the same table, the second ranked com-
parison is number two (normal × all tumors), as expected.
The error and average distance of triples that separate nor-
mal brain from neoplasic tissue are almost ten times larger
than the average distance between tumors. As far as the
tumor classes are concerned, the distance between grades
II and III is the highest. It may be observed from compar-
isons 3, 4, 5 and 6 in Table 2 that the average distances
tend to be smaller, reflecting the glioblastoma progression
from astrocytoma grade II to III. Astrocytoma grade III
Sample output table in HTML format Figure 1
Sample output table in HTML format. Sample of the output table produced by the system in HTML format (astrocytoma 
III × glioblastoma experiment).
Table 1: Anatomopathological comparisons. Anatomopathological comparisons and the number of libraries in each class (n = normal, 
a = astrocytoma grades II and III, g = glioblastoma, a2 = astrocytoma grade II, a3 = astrocytoma grade III). The symbol "O" represents 
samples of the first group, and "X" represents samples of the second group in Figures 2 and 3.
Comparison label Normal (2) Astrocytoma II (4) Astrocytoma III (9) Glioblastoma(9)
1 (normal × glio) O - - X
2 (normal × astro, glio) O X X X
3 (astro 2 × astro 3) - O X -
4 (astro 2 × astro 3, glio) - O X X
5 (astro 3 × glio) - - O X
6 (astro × glio) - O O XBMC Bioinformatics 2007, 8:169 http://www.biomedcentral.com/1471-2105/8/169
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seems to be between astrocytoma grade II and glioblast-
oma, as well as it seems to be closer to glioblastoma than
to astrocytoma grade II, although the differences are very
small.
According to Table 2, the credibility provides robustness
to the selection since the standard deviation of the dis-
tances and of the bolstered errors for the 50 first ranked
triples using the score are smaller than the counterpart
using only the error. Moreover, it may be observed that
the 10 most frequent genes in the first 50 triples for each
comparison depend on whether the score is used or not.
Discussion
One of the goals for gene expression profiling is to iden-
tify signatures of tumor types or grades. Attempts have
been made to classify gliomas based on gene expression
profiling [10,15,16] using the microarray technique.
Some molecular functions and biological processes are
over-represented in different tumor grades. Due to impor-
tant differences in the probabilistic models of microarray
and SAGE techniques, the concept of a subspace credibil-
ity based on the credibility intervals of SAGE measure-
ments was developed in order to complement the
application of the strong genes technique. The microarray
expression measurement is based on hybridization and
optical phenomena while SAGE is based on a direct
molecular counting process. Therefore, they have quite
different probabilistic distributions. The strong genes
technique is based on a Gaussian distribution model
whereas SAGE follows a binomial distribution. In such
conditions, the direct application of the strong genes tech-
nique to SAGE data is meaningful only for gene triples
that present highly separated classes. The concept of cred-
ibility intervals was precisely created to evaluate the signif-
icance of the application of the strong genes technique to
a binomial distribution expression measure. Furthermore,
the credibility intervals are estimated from the available
sample and increase for smaller sample sizes. Hence, the
condition for accepting gene triples measured from small
samples is very severe, i.e. they should produce very sepa-
rated classes to be accepted.
The presented results revealed that, by using the score
based on the spread error and the credibility, the selected
triples could separate the distinct classes. The credibility
analysis of strong genes was validated by comparing pre-
vious results of glioma microarray data analysis to the
results of its application to glioma SAGE data. Some genes
already described as related to glioma's invasion capacity
by microarray studies such as SPOCK1 [17], BCL2L2 [18],
EEF1A2 [15] and TMEFF1 [19] also appeared in the 50
first best triples. They are related to cell adhesion, regula-
tion of apoptosis and translation elongation. It is impor-
tant to notice that the pathways to which these genes
belong could help understanding the disease progression.
For example, it was shown that fibroblast growth factor-
inducible 14 (Fn14) is overexpressed in migrating glioma
cells in vitro and in glioblastoma multiforme clinical
specimens in vivo. The biological role of Fn14 in brain
cancer progression was correlated to Fn14 activation and
induction of BCL2L2 mRNA and protein levels, and this
effect depended on NFkappaB transcriptional activity
[20]. On the other hand, some retrieved genes that were
never related to gliomas progression but involved in struc-
Plot for the best triple of the astrocytoma III × glioblastoma  experiment Figure 3
Plot for the best triple of the astrocytoma III × gliob-
lastoma experiment. Three-dimensional plots= for the 
best gene triple produced by the system (astrocytoma III × 
glioblastoma experiment) with credibility interval boxes.
Plot for the best triple of the astrocytoma III × glioblastoma  experiment Figure 2
Plot for the best triple of the astrocytoma III × gliob-
lastoma experiment.Three-dimensional plots= for the 
best gene triple produced by the system (astrocytoma III × 
glioblastoma experiment) without credibility interval boxes.BMC Bioinformatics 2007, 8:169 http://www.biomedcentral.com/1471-2105/8/169
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tural/extracellular matrix-related genes or growth factor-
related genes, such as PARVA and SHOC2, appear among
the 10 most frequent genes in the 50 best triples only
when the score with credibility is applied. Besides,
because of the fact that structural/extracellular matrix-
related genes or growth factor-related genes have an
important role in glial tumors [21], it was recently sug-
gested that SHOC2 function is essential for activation of
MAPK pathway by growth factors [22].
However, other genes usually related to gliomas such as
VEGF or IGFBP2 were not present in the first triples. There
are some reasons for this fact. The first is that the VEGF
was excluded from the analysis by the adopted criterion of
tags exclusion (see Methods section). Even so, this gene
presented low representativity (large number of zeros for
both considered classes in all comparisons). For the case
of IGFBP2, this gene was included in the set of analyzed
genes, but the discrimination power is not enough to
appear in the best triples. Figures 4-7 shows four graphics
for the astrocytoma II and III versus glioblastoma compari-
son that illustrate the difference of the discrimination
power of VEGF and IGFBP2 with respect to COPS5 and
ZDHHC22. The two last ones presented the highest fre-
quencies in the first 50 best triples for the considered com-
parison.
The difference of the results presented by microarray and
SAGE methods may be explained by the particularities of
each method. The Spearman correlation between these
two methods is r = 0.6 in both absolute expression and
comparative analysis [23]. The microarray and SAGE
results tend to be consistent when both samples are large
enough and there are triples that produce highly separated
classes. In other conditions, such results may not be con-
sistent. In the case of the results here reported, the small
SAGE sample size explains why some well known glioma
genes were out of our best triples.
Conclusion
Even using the credibility intervals, which is feasible for
SAGE but not for microarray data, it is difficult to define
the "best triple" because of the small sample size and high
data variability. Because of such statistical limitations, it is
Table 2: Summary of comparisons. For each comparison, this table shows the 10 most frequent genes along the first 50 best triples 
ranked by bolstered error and score. Avg. Error = bolstered error; Avg. Dist. = average distance of the nearest point from the 
hyperplane; std. dev. = standard deviation.
Comparison normal × glio normal × astro, glio astro 2 × astro 3 astro 2 × astro3, glio astro 3 × glio astro 2, astro3 × glio
Ranked by avg. bolstered error
Avg. Error (std. dev.) 0.0 (0.0) 0.0 (0.0) 0.003 (0.0) 0.016 (0.003) 0.022 (0.004) 0.031 (0.003)
Avg. Dist. (std. dev.) 59.217 (90.175) 21.76 (0.35) 2.194 (0.297) 1.095 (0.222) 1.115 (0.256) 0.785 (0.199)
1 ITPKA CPNE7 SCN4B LOC646999 COPS5 COPS5
2 CPNE7 AK055475 GPX2 RPM2B WASF1 ZDHHC22
3 NDFIP2 TAIP-2 ZNF233 AK090819 SAP18 BC035881
4 KIAA1345 PCDH9 APBA3 RALGPS1 VPS35 WASF1
5 HLF LCE2D HSU79275 RP1-32F7.2 CHGB PRPF39
6 FLJ31636 AK095013 LRRC50 HSU79275 FLJ31818 LHFPL2
7 BX648951 C1QL2 HNF4G LRRC50 MORF4L1 ZNF644
8 CYP7B1 LOC36003 RAET1E FLJ20323 FLJ39538 POLDIP3
9 BC042456 GPR97 AX090819 DUSP9 ZNF233 ZBTB5
10 PIK3C3 GSTO2 MRC2 WDR35 DNASE2 LRP12
Ranked by score
Avg. Error (std. dev.) 0.0 (0.0) 0.0 (0.0) 0.006 (0.003) 0.021 (0.006) 0.028 (0.007) 0.033 (0.005)
Avg. Dist (std. dev.) 18.48 (1.17) 10.03 (0.23) 1.91 (0.23) 0.91 (0.32) 1.02 (0.28) 0.83 (0.21)
1 RPH3A CALM3 APBA3 RRM2B WASF1 COPS5
2 ITPKA SEPT5 PARVA RALGPS1 SAP18 ZDHHC22
3 HLF EEF1A2 BC023565 PDE8A COPS5 BC035881
4 NDFIP2 LCE2D BC015762 BDP1 ZDHHC22 SAP18
5 SH3GL2 PPP2R4 DNASE2 RP1-32F7.2 BC035881 ANAPC13
6 SYT13 SULT4A1 KBTBD6 TMEFF1 LRP4 LRP4
7 BCL2L2 ATP1A3 KCTD9 BC023565 JPH4 JPH4
8 MGC34830 VMP ZNF354C BC015762 CHGB PRPF39
9 PLEKHB2 PNMA6A C15orf29 ZNF354C ANAPC13 LHFPL2
10 DSCR1L1 FBXO2 SHOC2 C15orf29 POLDIP3 SSR3BMC Bioinformatics 2007, 8:169 http://www.biomedcentral.com/1471-2105/8/169
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more realistic to identify larger sets of genes in the top
position triples for posterior analysis. The introduced
methodology allows ranking a given number of best can-
didates to be subsequently analyzed in a complementary
way. The introduced method is suitable to define the tri-
ples that perform a good separation of the classes using
SAGE since it is possible to use data from different labora-
tories. It is important to note that our model may also be
applied for other counting methods such as Massive Par-
allel Signature Sequencing (MPSS) or the recent Sequenc-
ing-By-Synthesis (SBS) technique. Moreover, some of the
best triples identified by the proposed method may be
useful in the future to generate classifiers.
Methods
SAGE data
The input tables consist of 24 SAGE libraries, each corre-
sponding to one sample (2 from normal brain, 4 from
Discrimination power comparison Figure 7
Discrimination power comparison. Expression of 
ZDHHC22 for each library of the comparison astrocytomas 
II and III versus glioblastoma.
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Discrimination power comparison Figure 5
Discrimination power comparison. Expression of 
IGFBP2 for each library of the comparison astrocytomas II 
and III versus glioblastoma.
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Discrimination power comparison Figure 4
Discrimination power comparison. Expression of VEGF 
for each library of the comparison astrocytomas II and III 
versus glioblastoma.
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Discrimination power comparison Figure 6
Discrimination power comparison. Expression of 
COPS5 for each library of the comparison astrocytomas II 
and III versus glioblastoma.
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astrocytoma grade II, 9 from astrocytoma grade II and 9 from
glioblastoma). These libraries were obtained from SAGE
Genie [24,25]. Only full length genes which have a
unique 3' tag (not present as a 3' tag or an internal tag of
another full length) were considered. Tags that have 8 or
more A in their sequence were eliminated because ambig-
uous tags have the potential to represent the sum of
expression of several genes, thus artificially increasing the
observed tag frequency. The tag AAAAAAAAAA, which can
be derived from the poly(A) tail of many transcripts, is
seen at a relatively high frequency in most SAGE libraries,
which explains why we decided to avoid such tags. 28370
full lengths were initially considered. The application of
the above filtering criterion leads to 17599 genes that have
been analyzed. The expression abundance eij of a tag i in a
library j is the number of counts of the tag i in the corre-
sponding library j divided by the number of counts of all
tags in the library j.
Strong genes technique
Due to the small number of samples of the SAGE experi-
ments focused here, we could not afford to leave out a
subset of the data for testing. We decided then to use bol-
stered error with linear discriminant analysis (LDA) and
normal kernels to evaluate the quality of gene subsets, as
suggested by Kim et al. [10] and further developed by
Braga-Neto and Dougherty [26].
One of the main problems while selecting good genes and
designing classifiers is that the usual error rate estimates,
like resubstitution, leave-one-out or ten fold cross valida-
tion, present high variance [27]. This is specially relevant
in a small sample setting where it is not possible to leave
data out from classifier design for testing [28]. In order to
alleviate such problems, Kim et al. [10,29] proposed to
spread each sample using a kernel distribution. In a follow
up paper, Braga-Neto and Dougherty have generalized
this technique and shown how to best choose the distri-
bution parameters [26]. The general technique was called
bolstered error estimation. Genes that give rise to a classifier
with small bolstered error are called strong genes. The idea
of bolstered error estimation is to spread each sample
using a fixed probability distribution. We have used a cir-
cular normal distribution with fixed variance σ2 as in [10].
The bolstered error of a classifier is the mass of the proba-
bility distribution that is misclassified. Naturally if we
increase σ2, the estimated error will increase. Since we use
a circular normal distribution, the optimal classifier and
the respective bolstered error can be computed analyti-
cally for a fixed σ2 and a gene subset [10]. We denote this
bolstered error as εσ.
For σ = 0, ε0 is equal to the resubstitution error of the com-
puted linear classifier, a low-biased error estimator.
Model-based simulation investigated in [10] suggests that
for σ = 0.4, εσ is an unbiased error estimator and the bias
increases with σ. We focused on σ = 0.4 in order to use
conservative error estimates as in [10]. Another important
property of the bolstered error estimation is that its vari-
ance decreases with increasing σ. This fact ensures that the
estimator variance is smaller than the variance for resub-
stitution and leave-one-out. Leave-one-out variance is
high for small sample sets and it is usually larger than
resubstitution variance, which is equal to the bolstered
error for σ = 0. Moreover the small number of samples in
each comparison forced us to concentrate on very small
gene sets: three in our case, i.e. gene triples were searched.
Finally, in order to use the algorithm explained in [10], an
important practical issue had to be addressed, i.e. compu-
tational time. The very high number of tags or genes
(17599 in our experiments) translates into a huge number
of possible triples: 1.49 × 1012. Even with the analytic
solution for the classifier and bolstered error estimate, the
time required to explore all triples for a fixed σ would be
close to a year on a typical desktop computer. We decided
then to use the pre-processing algorithm proposed by
Silva [11] based on linear support vector machines. This
technique looks for a small group of genes that are able to
separate the data with high quality, in the sense that the
samples of different classes are linearly separable and far
away from each other. However, there is no way to control
the groups size and they turn out to be too large, usually
a few tens. After selecting a hundred genes using the pre-
processing algorithm, a full search of the possible triples
is carried out using the bolstered error. It was shown in
[11] that the pre-processing usually keeps the best gene
subsets even though the computation time takes only
some minutes. The criterion used by SVM to choose good
genes, a geometric distance of the two classes to the sepa-
rating hyperplane, is intuitively related to the bolstered
error estimator.
Actually, if the genes of a class are close to the decision
surface, the mass of a distribution centered on such sam-
ples that is incorrectly classified is expected to be high. On
the other hand, if the distance is large, the incorrectly clas-
sified portion of such distributions should decrease. This
correlation has been empirically verified in many tests
described in [11]. It is worth noting that the SVM does not
process each gene isolated. It searches the space of all
genes at the same time, implicitly taking all possible com-
binations into account. The SVM finds a small group that
presents the best discriminatory power according to the ∞-
norm criterion.
Considering that SAGE data usually contains dozens of
samples with thousands of tag counts, the strong genes
technique adopted here looks only for those triples that
provide the best linear separation of the classes. It is easy
to see that in this case there are many possible linear clas-BMC Bioinformatics 2007, 8:169 http://www.biomedcentral.com/1471-2105/8/169
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sifiers, unless the sample is very peculiarly disposed in
space. Finally, more expressive classifiers tend to overfit
the sample more easily and should be avoided. In cases
where the number of samples is large enough to justify the
use of nonlinear classifiers, nonlinear Support Vector
Machines based on (nonlinear) kernel functions may be
adopted to generalize our approach.
Credibility intervals
Once SAGE expression data is obtained by sampling (i.e.
counts of observed tags), it is important to have a credibil-
ity measure for each expression based on the total number
of tags counted in each library. This process may be mod-
eled by a Beta probability density function (pdf) [13]. Let
x be the number of counts of a given tag and b be the total
number of counts for all tags in a given library. The credi-
bility interval around x is calculated using the Beta pdf:
where f(i) indicates the probability of the real number of
counts be i given b and x.
Once a credibility value   is fixed, 0 <  < 1, the credibil-
ity interval extreme values t1 and t2 are obtained by inte-
grating f(i) around its mode so that f(t1) = f(t2) and
The distribution's mode coincides with the number of
counts of a given tag (i.e. it occurs at i = x) whenever a
non-informative uniform a priori distribution is assumed.
A credibility index is defined to characterize the discrimi-
nation power of each gene triple for libraries related to
two different biological states. The credibility index for a
given gene triple (selected by the strong gene method) is
calculated as follows. Firstly, the credibility interval for a
given credibility value   is calculated for each gene of
each library. For each library, the respective three credibil-
ity intervals define the vertices of a box. If there is no box
intersections between the libraries of one biological state
with the library boxes of the other biological state, then
the credibility index is increased. In case of non-empty
intersection, the credibility index is decreased. A binary-
search like procedure is applied to calculate the credibility
index from the libraries data. This binary-search proce-
dure starts with   = 0.5 and is repeated m times to pro-
duce the final credibility index. Larger m values lead to
more accurate credibility values. In our experiments, m =
7 was adopted.
Signature genes identification
A pipeline system has been implemented in order to inte-
grate the aforementioned SAGE analysis procedures. The
system takes as input the selected data as described in the
previous section (SAGE data) and pre-processes the data
to build a matrix with these libraries associated to the
selected comparison made by the user (e.g. astrocytoma III
versus glioblastoma). Then, the strong genes selection pro-
cedure is applied to this matrix, producing a table with
1000 best gene triples ordered by the bolstered error.
Although 1000 triples represent a much smaller set with
respect to all possibilities, it is too long to be analyzed by
human inspection. In order to identify triples that are
potential candidates for differential diagnosis of these
tumor types, the score given by Equation 3 is calculated
and assigned to each triple.
where Ei is the bolstered error of triple i, E is the vector of
these errors for all 1000 triples, Ci is the credibility value
of triple i, C is the vector of these credibilities for all 1000
triples, NE = max(E) - min(E) and NC = max(C) - min(C).
Lower scores lead to better triples. All the triples are
ranked by this score and we have chosen the first 50 from
each comparison for posterior analysis (see Results and
Discussion sections).
The system produces a series of output information in
HTML form: a table with all selected gene triples, the
number of libraries, the error, the distance between the
classes (i.e. biological states), the number of occurrences
of each gene in the list, the credibility value and the score
defined by Equation 3 (see an example in Figure 1). URL's
for 3D plots of each triple are produced by the system
(Figure 2).
Three-dimensional plots of the credibility interval boxes
are also generated (Figure 3). All output features were
designed to help the biological interpretation by the bio-
medical experts.
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